What Patients Should Know About Ozempic and Gastroparesis in New York

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

General Health and Science Information Context

If you or someone you know is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. Medical literature has historically focused on the benefits of semaglutide for metabolic health, but recent reports have prompted closer scrutiny of gastrointestinal risks. This page provides a factual overview of prescribing information and what current research says about the connection.

Transition to Specific Risk Assessment

This shift in focus brings us to the emerging occupational exposure concern: the potential link between Ozempic use and the development of gastroparesis—a condition of delayed gastric emptying that can significantly impact quality of life. In the legal and regulatory landscape, this concern has crystallized into questions about accountability and timelines for action. For individuals in New York who have used Ozempic and subsequently developed gastroparesis, understanding the statute of limitations is critical. This transition from general health information to specific legal and medical risk assessment marks a necessary evolution in how we approach medication safety and patient advocacy.

Gastroparesis and Ozempic: Clinical Evidence

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or, in severe cases, surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacology involves mimicking the action of endogenous GLP-1, which stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This latter effect is integral to its therapeutic action but also underlies many of its gastrointestinal adverse effects. Clinical trial data indicate that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In placebo-controlled trials, 32.7% of patients on Ozempic 0.5 mg and 36.4% on Ozempic 1 mg experienced such reactions, compared to 15.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for the 0.5 mg dose and 3.8% for the 1 mg dose, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (20.3% for 1 mg), vomiting (9.2%), diarrhea (8.8%), abdominal pain (5.7%), and constipation (3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Link and Risk Considerations

The mechanistic pathway linking Ozempic to gastroparesis is rooted in its effect on gastric motility. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to prolonged retention of gastric contents. In susceptible individuals, this pharmacodynamic effect may transition from a transient, dose-dependent slowing to a persistent state of gastroparesis, even after drug discontinuation. The reported adverse reactions of nausea, vomiting, and abdominal pain align with gastroparesis symptomatology, and the high incidence of these events in clinical trials suggests a dose-response relationship. Regarding risk anchors, the adequacy of warnings for Ozempic and gastroparesis is a critical consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly list gastroparesis as a specific adverse effect. The label notes that serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a direct warning for gastroparesis may be relevant in settlement considerations, as patients who developed this condition might argue that the risks were not adequately communicated.

Statute of Limitations for Ozempic Claims in New York

Settlement-related considerations for affected patients in New York involve the statute of limitations, which governs the time frame within which a lawsuit must be filed. In New York, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For claims involving medical monitoring or product liability, the timeline may vary. The timeline between exposure to Ozempic and documented harm is crucial. Patients who developed gastroparesis after starting Ozempic should document the onset of symptoms, the date of diagnosis, and any medical records linking the condition to the drug. Given that gastrointestinal adverse reactions often occur during dose escalation, the harm may manifest within weeks to months of initiation. However, gastroparesis can develop insidiously, and the statute of limitations may begin at the point of diagnosis or when the patient becomes aware of the potential link to Ozempic. In summary, the evidence indicates a clear association between Ozempic use and gastrointestinal adverse reactions, with mechanistic plausibility for gastroparesis. The adequacy of warnings remains a point of contention, and affected patients in New York must be mindful of the statute of limitations, which typically allows three years from discovery of harm. Legal counsel should be sought to evaluate individual circumstances, including the timing of exposure, symptom onset, and diagnosis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in New York?

In New York, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For Ozempic-related gastroparesis, this typically means three years from diagnosis or from when the patient became aware of the potential link to the drug.

Does Ozempic cause gastroparesis?

Clinical trial data show that gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, occur significantly more frequently with Ozempic than placebo. The mechanism of action—slowing gastric emptying—provides a plausible link to gastroparesis. However, the prescribing information does not explicitly list gastroparesis as a specific adverse effect.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.